NewsRoom Articles - Page 11 of 154 - PsychedelicNewsWire (PNW)

ThursdayMay 16, 2024 10:00 am

Vermont Lawmakers Send Modified Psychedelics Therapy Bill to Governor’s Desk

Legislators in Vermont have approved a measure that would establish a task force for psychedelic therapy. The group’s primary task would be to recommend how and whether the state should regulate legal access to psychedelic drugs such as MDMA and psilocybin. The legislation is now headed to the governor’s desk. Last week, the senate approved amended language of the legislation, approving changes made in the house. In its present form, the legislation wouldn’t amend the legal status of any drugs. Rather, the working group would review the latest evidence and research on public-health risks and benefits of clinical psychedelic-assisted therapies…

TuesdayMay 14, 2024 10:00 am

Majority of Americans That Have Used Psychedelics, Marijuana Report Positive Experiences

A survey conducted by YouGov has found that a majority of U.S. citizens have used marijuana before, and most of them revealed that the experience was a positive one. This survey also discovered that 20% of Americans have also tried “magic mushrooms” (psilocybin mushrooms), and an even bigger proportion of these users reported that the experience was a positive one. This poll comes at a time when the Biden administration is taking steps to reschedule marijuana while many states are also looking to reform their laws around psychedelics. The poll provides a deep dive into what Americans think of these…

ThursdayMay 09, 2024 10:00 am

Another Study Shows Efficacy of Psilocybin Against Depression

Depression is a leading cause of disability that affects roughly 300 million individuals around the globe. Now, new research has determined that psilocybin is an effective treatment for symptoms of depression. This is in comparison to niacin, which was administered as the placebo, and microdoses. Psilocybin is the primary active compound in more than 200 species of hallucinogenic mushrooms. The research findings, carried out by investigators in the United Kingdom, was published in the BMJ. In a statement, the researchers explained that psilocybin had shown promise in alleviating depression symptoms following the administration of one or two doses with few…

TuesdayMay 07, 2024 10:00 am

Deregulating Psychedelics Could Boost Clinical Studies

American researchers will be able to study various psychedelics and their effects on the human body much more effectively if hallucinogens are finally deregulated after decades of state and federal prohibition. Similar to how cannabis research opened up after dozens of states legalized either recreational or medical cannabis, policymakers hold the key to more comprehensive psychedelic clinical studies. Researchers typically have a significantly hard time accessing and researching controlled substances such as psychedelics, which makes them less inclined to research hallucinogenic drugs. However, with psychedelic use increasing across the country as more people turn to hallucinogens to alleviate their mental…

ThursdayMay 02, 2024 10:00 am

New Study Suggests Childhood Trauma Doesn’t Cause Challenging Ayahuasca Trips

A new study has disputed the common belief that experiencing trauma in one’s childhood may affect a user’s experience with ayahuasca. Ayahuasca is a psychoactive brew that has been used by Indigenous cultures in the Amazon and Orinoco basins for millennia for divination, spiritual ceremonies and healing. The brew is comprised of the Psychotria viridis shrub, which contains DMT, and the Banisteriopsis caapi vine. When ingested, this brew causes altered states of consciousness, which include vivid visions that can last for hours. Traditionally, these psychoactive experiences are sought for spiritual growth and healing and can be guided by experienced shamans.…

TuesdayApr 30, 2024 10:00 am

DEA Tells Court That Right to Try Law Doesn’t Supersede CSA in Psilocybin Case

The U.S. Drug Enforcement Administration (DEA) is claiming that a federal law that affords severely ill individuals the right to try investigational medications doesn’t apply to drugs classified under the Controlled Substances Act. This is in response to a lawsuit filed by a doctor in Washington state who sought permission to legally administer psilocybin as treatment for patients in end-of-life care with cancer. The agency argues that because drugs classified under Schedule I are said to have no accepted medical use, the law prevents them from being dispensed, even by professionals. The doctor in question, Dr. Sunil Aggarwal, has been…

ThursdayApr 25, 2024 10:00 am

Study Shows Ayahuasca’s Painkiller Effects in Mice, No Toxic Effects

Ayahuasca is a psychoactive brew that has been used for centuries by Indigenous cultures in South America for divination, spiritual ceremonies and healing. It is made from the Psychotria viridis shrub and the Banisteriopsis caapi vine, which contain DMT and harmala alkaloids, respectively. Interest in ayahuasca has grown in Europe and the United States over the last couple of years as people learn more about the brew’s potential therapeutic benefits in treating mental-health conditions such as anxiety, post-traumatic stress disorder and depression. Now, new research has found that the brew can be used as a painkiller without any toxic effects.…

TuesdayApr 23, 2024 10:00 am

Study Says Psychedelics Can Boost Sexual Satisfaction, Functioning

New research has looked into the influence of psychedelic substances on sexual functioning and satisfaction. This comes as scientists learn more about the promising potential of psychedelics in treating mental-health conditions. Various studies have looked into the effectiveness of psilocybin in alleviating symptoms of anxiety. Psilocybin, the primary psychedelic compound found in different species of hallucinogenic mushrooms, has also shown comparable effectiveness to escitalopram in reducing symptoms of depression in patients with major depressive disorder. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. SSRIs have different side effects, a common one being sexual dysfunction. Sexual dysfunction may lower an…

ThursdayApr 18, 2024 10:00 am

Therapist Explains What Psychedelics Do, What Talk Therapy Can’t

Interest in the use of psychedelics in therapy has increased over the last couple of years, with researchers finding that drugs such as psilocybin, LSD and ketamine may be useful in the treatment of different mental-health conditions. According to one therapist, psychedelics are drugs that enable the dissolution of the individual ego. This is the objective of many spiritual traditions, where one realizes that they aren’t an individual island living a separate life but a smaller cog in a huge machine. By the aforementioned definition, psychedelics include ayahuasca, DMT, ketamine, psilocybin and LSD. It is important to note MDMA is…

TuesdayApr 16, 2024 10:00 am

AMA Study Finds Treating Mental-Health Issues with Psilocybin Doesn’t Increase Paranoia Risk

A recently published review has determined that using psilocybin to manage mental-health conditions doesn’t heighten the risk of paranoia. This discovery comes at a time when public interest in the therapeutic potential of psychedelics is increasing. The review was carried out by researchers at Larkin University, the University of Georgia and Palm Beach Atlantic University, who were focused on better understanding the potential negative effects of psilocybin therapy. For their study, the researchers reviewed six randomized, double-blind clinical trials with a total of 528 patients, where psilocybin was administered to treat depression and anxiety. They used ClinicalTrials.gov, Web of Science…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000